Spotlight on JLABS

Tuesday, May 23, 2017 | 11:15 a.m. - 1:00 p.m. Add to Calendar

Interested in starting a company, investing, or just curious about the current state of innovation in Houston? Then YOU are invited to JLABS @ TMC on May 23rd to meet, greet, and see short presentations on some of our standout companies. Space is limited, so don’t miss out! Did you know that JLABS @ TMC is home to nearly 35 emerging companies? On May 23rd, JLABS will shine the spotlight on three of our resident companies: InPRO Medical, Kode Biotech and Vax-Immune. Join us to see how they’re moving innovation forward, right here in Houston.

Please note that the presentations at this event will include publicly available, non-confidential information only.

Date: Tuesday, May 23, 2017


11:15 AM | Registration Opens

11:30 AM | Networking Lunch

12:00 PM | Presentations

1:00 PM | Program Close


RSVP: Please RSVP online so that we can get an accurate headcount for food and beverages.

Presenting Companies’ Descriptions:

InPRO Medical is developing a solution for hospitals to eliminate hospital-acquired pressure ulcers. Our solution provides an integrated analytics platform in which data is collected through a suite of wearable sensors. Using our tool care providers can continuously monitor and visualize pressure ulcer risks for each patient and implement a protocol to ensure patients are repositioned in optimal intervals to minimize the risk of developing pressure ulcers. Our technology provides hospitals significant cost savings of up to $100K per patient per stay and improves the quality of life of the patients.

Kode Biotech USA is the US subsidiary of Kode Biotech, based in Auckland, New Zealand. We have developed an easy, fast, versatile, and controllable technology to modify biological surfaces (cells, viruses…) and non-biological surfaces (stainless steel, plastics…). Being able to easily change surface functionality has broad applications in therapeutics, diagnostics, and consumer products. There are several Kode-based products in the R&D and diagnostics markets generating revenue, one about to start Phase I/II clinical trials, with other prototype products being evaluated or in development. Our mission is to get our technology licensed broadly as a core component that enables the next generation of therapeutics, diagnostics, and high-value consumer products.

Vax-Immune’s LabReady® is a unique platform technology that eliminates false negative cultures by bringing the lab to the patient. LabReady® makes the diagnosis of infection faster, simpler, easier, less expensive, and more accurate. It re-imagines the laboratory where everything happens before the sample arrives. LabReady® is a proprietary, portable, disposable, hand-held device. It collects, processes, and grows the sample beginning at the patient and through transport, so when it arrives at the laboratory the infection can be diagnosed. LabReady® strips out the inefficient time lapse between sample collection and diagnosis. Vax-Immune re-imagines a world where infection is diagnosed and treated anywhere, anytime, and in the process lives are saved and costs are reduced. LabReady® — Taking the lab to the point of care®



2450 Holcombe Blvd. Suite J


Katelyn Balch

(346) 772-2304